- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
26 result(s) found for: Deep sequencing.
Displaying page 1 of 2.
EudraCT Number: 2014-004927-27 | Sponsor Protocol Number: RELAIS | Start Date*: 2014-12-17 |
Sponsor Name:Med. Univ. Wien, Innere Med. I | ||
Full Title: REgorafenib’s Liquid BiopsY (RELY): A multicenter translational biomarker phase II trial of regorafenib in patients with non-resectable pretreated colorectal cancer. a non-profit investigator-init... | ||
Medical condition: non-resectable pretreated colorectal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000799-32 | Sponsor Protocol Number: PROTEST | Start Date*: 2011-06-08 | |||||||||||
Sponsor Name:Fundació Lluita contra la SIDA | |||||||||||||
Full Title: Use of genotypic HIV-1 tropism testing in proviral DNA to guide CCR5 antagonist treatment in subjects with undetectable HIV-1 viremia | |||||||||||||
Medical condition: Human immunodeficiency virus (HIV) infection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000358-26 | Sponsor Protocol Number: BETAF-RED | Start Date*: 2022-05-11 | |||||||||||
Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer | |||||||||||||
Full Title: Safety, tolerability, and efficacy of a dose reduction strategy based on bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-infected adults. | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004355-33 | Sponsor Protocol Number: MH002-UC-201 | Start Date*: 2021-09-23 | |||||||||||
Sponsor Name:MRM Health NV | |||||||||||||
Full Title: Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Mechanistic Effects, and Effects on Disease Activity of MH002 in Subjects with Mild to Moderate Ulcerative Colitis: A First-in... | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004557-24 | Sponsor Protocol Number: UKM17_0056 | Start Date*: 2019-07-29 | |||||||||||
Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel | |||||||||||||
Full Title: Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001571-32 | Sponsor Protocol Number: APHP200406 | Start Date*: 2020-04-15 |
Sponsor Name:Assistance Publique Hôpitaux de Paris | ||
Full Title: Low dose of IL-2 In Acute respiratory DistrEss syndrome related to COVID-19 LILIADE-COVID | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005394-31 | Sponsor Protocol Number: 12/0219 | Start Date*: 2014-04-01 |
Sponsor Name:UCL | ||
Full Title: MS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis | ||
Medical condition: Mutliple Sclerosis (Secondary Progressive) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-005121-21 | Sponsor Protocol Number: THEROS | Start Date*: 2018-11-13 | |||||||||||
Sponsor Name:Universitätsklinikum Essen | |||||||||||||
Full Title: Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabol... | |||||||||||||
Medical condition: Non-small-cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003481-13 | Sponsor Protocol Number: NEAT44 | Start Date*: 2019-01-15 | |||||||||||
Sponsor Name:NEAT ID Foundation | |||||||||||||
Full Title: An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease. The Late Presenter ... | |||||||||||||
Medical condition: Patients who present late on during their acquisition of the HIV-1 (Human Immunodeficiency Virus) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Ongoing) ES (Ongoing) BE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003000-39 | Sponsor Protocol Number: 2018.0158 | Start Date*: 2019-01-09 | |||||||||||
Sponsor Name:St George’s University of London | |||||||||||||
Full Title: A Multi-centre, Multiple-dose, Open-label Study to Investigate the Safety, Tolerability, Pharmacodynamics, and Efficacy of Erythrocyte Encapsulated Thymidine Phosphorylase (EE-TP) in Patients with ... | |||||||||||||
Medical condition: Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-005028-40 | Sponsor Protocol Number: MOLTO | Start Date*: 2019-08-29 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA | |||||||||||||
Full Title: A Multi-Center, Open Label, Uncontrolled, Phase II Clinical Trial Evaluating the Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL | |||||||||||||
Medical condition: Richter syndrome of chronic lymphocytic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000782-53 | Sponsor Protocol Number: UNITO-MM-01/FORTE | Start Date*: 2015-01-12 |
Sponsor Name:Università degli Studi di Torino-Dipartimento di Biotecnologie Molecolari e Scienze della Salute | ||
Full Title: A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as pre transplant INDUCTION and post transplant consolidation or CARFILZOMIB, LENALIDO... | ||
Medical condition: NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004106-34 | Sponsor Protocol Number: Dastop2October17th2016 | Start Date*: 2017-03-06 |
Sponsor Name:Uppsala University Hospital | ||
Full Title: PERSISTENCE OF MAJOR MOLECULAR REMISSION IN CHRONIC MYELOID LEUKEMIA AFTER a second stop of TKI TREATMENT in patients who failed an initial stop attempt: A prospective multicenter study . | ||
Medical condition: Chronic Myeloid Leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) DK (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003296-34 | Sponsor Protocol Number: OTX116505 | Start Date*: 2014-01-29 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Oteli... | |||||||||||||
Medical condition: NOT1DM is an autoimmune disease. This means that the immune system, the part of the body which usually helps to fight infections, mistakenly attacks cells that produce insulin in the body. Insulin ... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005531-13 | Sponsor Protocol Number: MED3-201401 | Start Date*: 2015-11-26 |
Sponsor Name:Univerity of Bonn | ||
Full Title: Multicenter, open-label single arm phase II study testing the tolerability and the efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Imatinib, ... | ||
Medical condition: Chronic Phase Chronic myelogenous leukaemia( CP-CML) patients who either developed intolerance or treatment failure to previous Imatinib, Dasatinib or Nilotinib as 1st or 2nd line therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-002106-68 | Sponsor Protocol Number: CTU/2020/354 | Start Date*: 2020-07-16 | |||||||||||
Sponsor Name:University College London Comprehensive Clinical Trial Unit | |||||||||||||
Full Title: Favipiravir, lopinavir/ritonavir or combination therapy: a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 | |||||||||||||
Medical condition: SARS-CoV-2 (Corona virus) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002806-28 | Sponsor Protocol Number: SOLTI-1502 | Start Date*: 2019-10-25 |
Sponsor Name:SOLTI | ||
Full Title: TARGETING THE PAM50 HER2-ENRICHED PHENOTYPE WITH ENZALUTAMIDE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER | ||
Medical condition: Male or pre/post-menopausal women age ≥ 18 years with advanced HR+/HER2-negative locally advanced/metastatic breast cancer resistant to endocrine therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001102-34 | Sponsor Protocol Number: CML1315 | Start Date*: 2015-09-15 | |||||||||||
Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS | |||||||||||||
Full Title: Optimizing Ponatinib USe (OPUS). Studio GIMEMA di fase 2 sull¿efficacia e sul profilo di rischio di ponatinib, 30 mg al giorno, in pazienti con Leucemia Mieloide Cronica (LMC) in Fase Cronica, resi... | |||||||||||||
Medical condition: Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004213-41 | Sponsor Protocol Number: 5172-048 | Start Date*: 2014-05-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. | |||||||||||||
Full Title: A Phase II Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects with Chronic Hepatitis C Virus Infection who failed prior Dire... | |||||||||||||
Medical condition: Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001691-41 | Sponsor Protocol Number: EMN29 | Start Date*: 2021-12-28 | |||||||||||
Sponsor Name:European Myeloma Network | |||||||||||||
Full Title: A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPL... | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma (RRMM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
